Sr. No.	Title	Project	Application	Patent No	Country
1	An improved process for the preparation of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine	Lamotrigine	99956293.7	1140872	Europe
2	An improved process for the preparation of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine	Lamotrigine	2171/CAL/98	183150	India
3	Process for preparation of the high melting polymorphic form of phenyl acetic acid derivative	Repaglinide	189/CAL/2001	189640	India
4	New process for preparation of biologically active isoxazole	Leflunomide	250/CAL/2002	193215	India
5	Process for purification of sulfinyl benzimidazoles	Rabeprazole	285/CAL/2002	192030	India
6	New process for preparation of biologically active benzisoxazole	Risperidone	507/CAL/02	224780	India
7	Improved process for preparation of biologically active phenylethylamine	Venlafaxine	78/KOL/03	194085	India
8	Process for synthesis of pharmaceutically active compound	Nebivolol	246/KOL/03	221733	India
9	Process for purification of Ropinirole	Ropinirole	66/KOL/2004	219077	India
10	Novel resolving agent	Resolving Agent	215/KOL/2004	232518	India
11	Acid Addition salt of Risperidone and Pharmaceutical Compositions Thereof	Risperidone Acid Salt	14/114379	9,040,695	USA
12	Acid Addition salt of Risperidone and Pharmaceutical Compositions Thereof	Risperidone Acid Salt	12723913.5	2702060	EUROPE
13	Acid Addition salt of Risperidone and Pharmaceutical Compositions Thereof	Risperidone Acid Salt	E767432	Validation of EP2702060	Austria
14	Acid Addition salt of Risperidone and Pharmaceutical Compositions Thereof	Risperidone Acid Salt	2702060	Validation of EP2702060	Belgium
15	Acid Addition salt of Risperidone and Pharmaceutical Compositions Thereof	Risperidone Acid Salt	2702060	Validation of EP2702060	Finland
16	Acid Addition salt of Risperidone and Pharmaceutical Compositions Thereof	Risperidone Acid Salt	2702060	Validation of EP2702060	France
17	Acid Addition salt of Risperidone and Pharmaceutical Compositions Thereof	Risperidone Acid Salt	60 2012 013 377.5	Validation of EP2702060	Germany
18	Acid Addition salt of Risperidone and Pharmaceutical Compositions Thereof	Risperidone Acid Salt	2702060	Validation of EP2702060	Greece
19	Acid Addition salt of Risperidone and Pharmaceutical Compositions Thereof	Risperidone Acid Salt	E12723913	Validation of EP2702060	Hungary
20	Acid Addition salt of Risperidone and Pharmaceutical Compositions Thereof	Risperidone Acid Salt	2702060	Validation of EP2702060	Italy
21	Acid Addition salt of Risperidone and Pharmaceutical Compositions Thereof	Risperidone Acid Salt	2702060	Validation of EP2702060	Netherlands
22	Acid Addition salt of Risperidone and Pharmaceutical Compositions Thereof	Risperidone Acid Salt	2702060	Validation of EP2702060	Poland
23	Acid Addition salt of Risperidone and Pharmaceutical Compositions Thereof	Risperidone Acid Salt	12723913.5	Validation of EP2702060	Portugal
24	Acid Addition salt of Risperidone and Pharmaceutical Compositions Thereof	Risperidone Acid Salt	EP/00349/2016	Validation of EP2702060	Romania
25	Acid Addition salt of Risperidone and Pharmaceutical Compositions Thereof	Risperidone Acid Salt	2702060	Validation of EP2702060	Turkey
26	Acid Addition salt of Risperidone and Pharmaceutical Compositions Thereof	Risperidone Acid Salt	2702060	Validation of EP2702060	Spain
27	Acid Addition salt of Risperidone and Pharmaceutical Compositions Thereof	Risperidone Acid Salt	2702060	Validation of EP2702060	UK
28	A process for the preparation of mono-substituted propenoic acid esters	IN-II	1137/CAL/ 98	186609	India
29	An improved process for the preparation of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine	Lamotrigine	(Validation)	Validation of EP 1140872	UK

30	An improved process for the preparation of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine	Lamotrigine	09/456,501	6111101	USA
31	Process for preparation of ß-phenethylamine derivative	Sibutramine	612/CAL/2000	187600	India
32	An improved process for preparation of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dionemaleate	Rosiglitazone	714/CAL/2000	193174	India
33	Improved process for the preparation of rivastigmine	Rivastigmine	682/MUM/2004	248778	India
34	Novel process for the preparation of Lercanidipine	Lercanidipine Cognate	1593/ MUM/2005	266785	India
35	Process for preparation of the polymorphic form	Sertraline (Polymorph)	628CAL 2002	205524	India
36	Process for preparation of polymorphic form of Sertraline Hydrochloride	Sertraline (Polymorph)	2005117371	2310647	Russia
37	An improved process for the preparation of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine	Lamotrigine	2334937	2334937	Canada
38	An improved process for the preparation of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine	Lamotrigine	1140872	Validation of EP 1140872	Germany
39	An improved process for the preparation of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine	Lamotrigine	20001115698	2231526	Russia
40	A process for the preparation of CIS-(1S,4S)-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthaleneamine hydrochloride	Sertraline	748/CAL/99	185109	India
41	An improved process for the preparation of pyridine derivative	Rosiglitazone	09/951481	6515132	USA
42	Montelukast Benzhydryl Piperadine Salts and Process for Preparation Thereof	Montelukast-Salt	9719393.2	2231613	Europe
43	A process for producing purified biologically active, free form of recombinant human interferon gamma	Interferon	49/CAL/2000	187900	India
44	Controlled release formulation for water soluble drugs and process for preparing it	ISMN	97/CAL/2001	207119	India
45	Process for preparation of a controlled release formulation for water soluble drugs	ISMN	23/KOL/2004	200148	India
46	Controlled release formulation of lamotrigine	Lamotrigine-OD	2488868	2488868	Canada
47	Controlled release formulation of lamotrigine	Lamotrigine-OD	00393/MUMNP/2004	214218	India
48	Controlled release formulation of lamotrigine	Lamotrigine-OD	00051/MUMNP/2004	203898	India
49	Controlled release formulation of lamotrigine	Lamotrigine-OD	2004139088	2328274	Russia
50	Controlled release formulation of lamotrigine	Lamotrigine-OD	10452772	7939102	USA
51	A process for the preparation of modified release dosage form	Platform, Single (Metformin)	(696 & 698/Mum/2002 & 81/Mum/2003)	193041	India
52	Novel Drug Delivery System	Platform, Single (Metformin)	198/MUM/2004	244585	India
53	Novel Drug Delivery System	Platform Single (Metformin)	1012/ MUM/2005	244675	India

54	Novel Drug Delivery System	Platform single (Metformin)	10/630,348	8216609	USA
55	Novel Drug Delivery System	Platform single (Metformin)	11/134,632	8268352	USA
56	Novel Drug Delivery System	Platform single (Metformin)	11/134,631	7976871	USA
57	Pharmaceutical Compositions	Entacapone	12/097,453	8772346	USA
58	A process for the preparation of a dosage form	Platform, Combination (Rosi+Met)	(697 & 699/Mum/2002 and 80 & 82/Mum/2003)	193042	India
59	Novel Dosage form	Platform, Combination (Rosi+Met)	197/MUM/2004	233453	India
60	Novel Dosage Form	Platform Combination (Rosi+Met)	1013/ MUM/ 2005	251149	India
61	Novel dosage form	Platform, Combination (Rosi+Met)	03758649.2	1528917	Europe
62	Novel dosage form	Platform, Combination (Rosi+Met)	1528917	Validation of EP 1528917	Germany
63	Novel dosage form	Platform, Combination (Rosi+Met)	1528917	Validation of EP 1528917	France
64	Novel dosage form	Platform, Combination (Rosi+Met)	1528917	Validation of EP 1528917	UK
65	Novel dosage form	Platform, Combination (Rosi+Met)	10/630,446	7985422	USA
66	Novel Dosage Form	Platform Combination (Rosi+Met)	11/134,633	8263125	USA
67	Once a day orally administered pharmaceutical compositions	PPI + PRO (Mosapride & Domperidon)	180/MUM/2003	196117	India
68	Once a day orally administered pharmaceutical compositions	PPI + PRO (Mosapride & Domperidon)	196/MUM/2004	224692	India
69	Solid oral Pharmaceutical Compositions of Aspirin and Process for Preparation Thereof	Clopidogrel + Aspirin	1493/MUM/05	235473	India
70	Sustained Release Pharmaceutical Composition of Quetiapine and Process for Preparation thereof	Quetiapine-SR-New	10717870.9	2373319	Europe
71	Sustained Release Pharmaceutical Composition of Quetiapine and Process for Preparation thereof	Quetiapine-SR-New	602010009060.4	Validation of EP23733319	Germany
72	Sustained Release Pharmaceutical Composition of Quetiapine and Process for Preparation thereof	Quetiapine-SR-New	EP(UK)2373319	EP(UK)2373319	UK
73	Pharmaceutical Composition Containing Goserelin for in Situ Implant	Goserelin	13/805,624	US9364518	USA
74	Pharmaceutical Composition of Tapentadol For Parenteral Administration	Tapentadol LAI	14/439,840	96,29,818	USA
75	A process for the preparation of pharmaceutical composition of ciprofloxacin	Ciprofloxacin	24/KOL/2004	202520	India
76	Pharmaceutical compositions having casing with multiple micro tablets	Venlafaxine SR	1045/MUM/2003	209877	India

77	Water Dispersible Tablet	Lamotrigine Disp Tab	1128/MUM/2003	213867	India
78	Controlled release formulation of lamotrigine	Lamotrigine-OD	03748504-2	1513535	Europe
79	Controlled Release formulation of Lamotrigine	Lamotrigine-OD	1513535	Validation of EP 1513535	Belgium
80	Controlled Release formulation of Lamotrigine	Lamotrigine-OD	1513535	Validation of EP 1513535	Bulgaria
81	Controlled Release formulation of Lamotrigine	Lamotrigine-OD	1513535	Validation of EP 1513535	Denmark
82	Controlled Release formulation of Lamotrigine	Lamotrigine-OD	1513535	Validation of EP 1513535	Finland
83	Controlled Release formulation of Lamotrigine	Lamotrigine-OD	1513535	Validation of EP 1513535	France
84	Controlled Release formulation of Lamotrigine	Lamotrigine-OD	60322389.3-08	Validation of EP 1513535	Germany
85	Controlled Release formulation of Lamotrigine	Lamotrigine-OD	1513535	Validation of EP 1513535	Greece
86	Controlled Release formulation of Lamotrigine	Lamotrigine-OD	1513535	Validation of EP 1513535	Italy
87	Controlled Release formulation of Lamotrigine	Lamotrigine-OD	1513535	Validation of EP 1513535	Luxemburg
88	Controlled Release formulation of Lamotrigine	Lamotrigine-OD	1513535	Validation of EP 1513535	Netherlands
89	Controlled Release formulation of Lamotrigine	Lamotrigine-OD	1513535	Validation of EP 1513535	Portugal
90	Controlled Release formulation of Lamotrigine	Lamotrigine-OD	1513535	Validation of EP 1513535	Romania
91	Controlled Release formulation of Lamotrigine	Lamotrigine-OD	1513535	Validation of EP 1513535	Spain
92	Controlled Release formulation of Lamotrigine	Lamotrigine-OD	1513535	Validation of EP 1513535	Sweden
93	Controlled Release formulation of Lamotrigine	Lamotrigine-OD	1513535	Validation of EP 1513535	Turkey
94	Controlled Release formulation of Lamotrigine	Lamotrigine-OD	1513535	Validation of EP 1513535	UK
95	Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol	Nebivolol	2005278782	2005278782	Australia
96	Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol	Nebivolol	2007/00765	2007/00765	South Africa
97	Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol	Nebivolol	2007106103	2378272	Russia
98	Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol	Nebivolol	200580025850.6	200580025850.6	China
99	Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol	Nebivolol	05.815690.2	1737847	Europe
100	Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol	Nebivolol Validation	381-03-012/0297	Validation of EP 1737847	Croatia

101	Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol	Nebivolol Validation	1737847	Validation of EP 1737847	France
102	Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol	Nebivolol Validation	60 2005 007 339.6-08	Validation of EP 1737847	Germany
103	Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol	Nebivolol Validation	49016 BE 2008	Validation of EP 1737847	Italy
104	Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol	Nebivolol Validation	1737847	Validation of EP 1737847	Iceland
105	Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol	Nebivolol Validation	1737847	Validation of EP 1737847	Lithuania
106	Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol	Nebivolol Validation	1737847	Validation of EP 1737847	Poland
107	Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol	Nebivolol Validation	1737847	Validation of EP 1737847	Romania
108	Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol	Nebivolol Validation	ES 2307219 T3	Validation of EP 1737847	Spain
109	Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol	Nebivolol Validation	1737847	Validation of EP 1737847	Turkey
110	Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol	Nebivolol Validation	1737847	Validation of EP 1737847	UK
111	Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol	Nebivolol	60216454	1741712	Europe